Full prescription coverage , reduced copayments , FDC and counselling were facilitators associated with higher adherence .
BACKGROUND Secondary prevention is cost-effective for cardiovascular disease ( CVD ) , but uptake is suboptimal .
Underst and ing barriers and facilitators to adherence to secondary prevention for CVD at multiple health system levels may inform policy .
OBJECTIVES To conduct a systematic review of barriers and facilitators to adherence/persistence to secondary CVD prevention medications at health system level .
Cardiovascular risk assessment and treatment to target low density lipoprotein levels in hospitalized ischemic heart disease patients: results of the HOLEM study.
BACKGROUND Hypercholesterolemia control status is lacking throughout the western world . OBJECTIVES To examine whether the treatment recommendations given to ischemic heart disease patients at hospital discharge are compatible with the guidelines of the Israeli medical societies and the U.S. National Cholesterol Education Program for coronary artery disease prevention ; and to study the effects of brief educational sessions on the adherence of physicians with the guidelines . METHODS We included consecutive IHD patients admitted to four central hospitals in Israel between 1998 and 2000 . The study was conducted in two phases . In phase 1 , we review ed discharge letters to document treatment recommendations given to each patient . In phase 2 we educated the practitioners by review ing the Israeli medical societies and the NCEP guidelines and the quality of their recommendations in phase 1 , after which we reevaluated the discharge letters . RESULTS The study included 2,994 patients : 627 in phase 1 and 2,367 in phase 2 . Of the patients who needed cholesterol-lowering according to their low density lipoprotein levels  , 37.4 % were not prescribed such drugs at discharge ( under-treatment group ) . This proportion was reduced by education to 26.6 % ( P < 0.001 ) in phase 2 . Of the treated patients , 65.6 % did not reach the target LDL goal in phase 1 ( under-dosage group ) as compared to 60.2 % in phase 2 ( P = 0.23 ) . In phase 2 there was an increase in the percent of patients reaching LDL levels < 130 mg/day ( 69.3 % vs. 63.8 % of patients prescribed medication , P = 0.01 ) , but the percent of patients reaching ' LDL levels < 100 was not different in phase 2 after adjusting for age and gender ( the odds ratio for reaching target LDL was 1.16 , with 95 % confidence interval of 0.95 - 1.43 ) . CONCLUSIONS Physician recommendations to IHD patients discharged from hospital were suboptimal . We documented a high proportion of under-treated and under-dosaged patients . Brief educational sessions have a beneficial effect on the usage of statins ; however , additional effort in guideline implementations is needed
Full prescription coverage , reduced copayments , FDC and counselling were facilitators associated with higher adherence .
BACKGROUND Secondary prevention is cost-effective for cardiovascular disease ( CVD ) , but uptake is suboptimal .
Underst and ing barriers and facilitators to adherence to secondary prevention for CVD at multiple health system levels may inform policy .
OBJECTIVES To conduct a systematic review of barriers and facilitators to adherence/persistence to secondary CVD prevention medications at health system level .